FDA accepts AstraZeneca's new Hyperkalaemia drug application for review
Tuesday, October 18, 2016
FDA accepts for review new drug application for sodium zirconium cyclosilicate (zs-9) for the treatment of Hyperkalaemia.
FDA has indicated that this is a complete class 2 response.
Interactions with other health authorities in European Union and Australia are ongoing with decisions expected in first half of 2017.
Source : reuters.com
